Chinese english Germany Korea


N-メチルホルムアミド 化学構造式
N-メチルホルムアミド;N-ホルミルメチルアミン;N-モノメチルホルムアミド;(メチルアミノ)ホルムアルデヒド;N-メチルホルムイミド酸;Nメチルホルムアミド;N-メチルホルムアミド(NMF);N‐メチルホルムアミド;N-メチルホルムアミド, 99%
x188;X 188;ek7011;EK 7011;nsc3051;HCONHCH3;NSC 3051;Methylformamide;Formylmethylamine;n-methyl-formamid
MOL File:

N-メチルホルムアミド 物理性質

融点 :
-3.2 °C
沸点 :
199 °C
比重(密度) :
1.011 g/mL at 25 °C(lit.)
屈折率 :
n20/D 1.432(lit.)
闪点 :
>230 °F
soluble in water, chloroform, alcohols, acetone, ethylacetate but not in diethyl ether and petroleum ether
外見 :
Clear colorless
Relative polarity:
水溶解度 :
Merck :
CAS データベース:
123-39-7(CAS DataBase Reference)
Formamide, N-methyl-(123-39-7)
N-Methylformamide (123-39-7)
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  T
Rフレーズ  61-21-R61-R21
Sフレーズ  53-45-S53-S45
WGK Germany  1
RTECS 番号 LQ3000000
容器等級  II
HSコード  29241990
有毒物質データの 123-39-7(Hazardous Substances Data)
毒性 LD50 in mice (mg/kg): 2300 i.p.; 2600 orally; 1580 i.v.; 2700 i.m. (Langdon)
消防法 危険物第4類第三石油類(水溶性)
化審法 (2)-679
注意喚起語 Danger
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H312 皮膚に接触すると有害 急性毒性、経皮 4 警告 P280,P302+P352, P312, P322, P363,P501
H360 生殖能または胎児への悪影響のおそれ 生殖毒性 1A, 1B 危険
P201 使用前に取扱説明書を入手すること。
P280 保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。
P308+P313 暴露または暴露の懸念がある場合:医師の診断/手当てを 受けること。
P405 施錠して保管すること。

N-メチルホルムアミド 価格 もっと(31)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01AFAL03908 N-メチルホルムアミド, 99%
N-Methylformamide, 99%
123-39-7 250g ¥8120 2020-09-21 購入
富士フイルム和光純薬株式会社(wako) W01AFAL03908 N-メチルホルムアミド, 99%
N-Methylformamide, 99%
123-39-7 50g ¥48800 2020-09-21 購入
東京化成工業 F0059 N-メチルホルムアミド >99.0%(GC)
N-Methylformamide >99.0%(GC)
123-39-7 500g ¥6900 2020-09-21 購入
東京化成工業 F0059 N-メチルホルムアミド >99.0%(GC)
N-Methylformamide >99.0%(GC)
123-39-7 25g ¥2100 2020-09-21 購入
関東化学株式会社(KANTO) 25260-30 N‐メチルホルムアミド >99.0%(GC)
N‐Methylformamide >99.0%(GC)
123-39-7 25g ¥2100 2020-09-21 購入

N-メチルホルムアミド 化学特性,用途語,生産方法




N-Methylformamide is used in amidation or transamidation chemical reactions where formamide is insufficient.




ChEBI: A member of the class of formamides having a N-methyl substituent.


N-Methylformamide (NMF) can be synthesized by: (1) reacting methylamine, carbon monoxide, methanol and a small amount of potassium acetate at 250 atm and 160°C; (2) heating methylamine with carbon monoxide and some sodium ethoxide in ethanol at 150 atm; (3) treating methylformate with methylamine and methanol; (4) reacting hexamethylenetetramine with formamide and hydrogen in the presence of Raney nickel at 130-145°C (Beilstein's Handbuch, 1977).


Clear colorless liquid with a slight amine odor.


Water soluble.


N-Methylformamide is incompatible with benzene sulfonyl chloride. N-Methylformamide is also incompatible with strong oxidizing agents, acids, bases and acid chlorides. N-Methylformamide may react with chlorine, bromine, nitrates, nitric acid, triethylaluminum, potassium permanganate, chromic acid, chromic anhydride, chromium trioxide, borohydrides, hydrides, thionyl chloride, metallic sodium, phosphorus trioxide, diborane, (octafluoroisobutyrate + sodium nitrite) and (perchloryl fluoride + potassium methyl 4,4-dinitrobutyrate).


As NMF is an investigational anticancer drug, a number of clinical trials have been conducted with this chemical. The first clinical evaluation was initiated in 1956 (Laird Myers et al 1956). Five patients were treated with NMF; all but one patient received the drug orally. The dose ranged from 0.1 g to 4 g per day for 2-36 days. All patients showed symptoms of toxicity - chiefly anorexia, nausea, and vomiting. Hepatic damage as measured by liver function tests was seen in all patients at total doses between 80-870 mg/kg. The liver damage appeared to be reversible with cessation of treatment. Autopsy examination of the liver of one patient showed irregular lobular disorganization, some large hepatocytes and areas of liver regeneration. McVie et al (1984) administered NMF i.v. and orally to 19 patients at a starting dose of 300 mg/m2/day for 5 days. Treatment cycles were repeated every 2 weeks and doses were escalated to 1200 mg/m2/day for 5 days. Ettinger et al (1985) treated 35 patients with NMF i.v. at doses ranging from 125-3125 mg/m2 weekly every 6 weeks. The principal toxic effects of NMF were general malaise, nausea, vomiting and anorexia. Biochemical disturbances included reversible elevation of serum levels of transaminases in several patients. The occurrence of raised serum enzyme levels did not seem to be related to the dose. Other toxic symptoms were peripheral neuropathy and alcohol intolerance in a few patients
Eisenhauer et al (1986) conducted a phase 2 clinical trial which was terminated early because of NMF-induced hepatic and gastrointestinal toxicity.


N-Methylformamide is combustible.


NMF possesses excellent solvent properties that are similar to those of dimethylformamide. However, NMF appears to be much less important as an industrial solvent than dimethylformamide.


Moderately toxic by ingestion, intraperitoneal, intravenous, intramuscular, and subcutaneous routes. An experimental teratogen. Experimental reproductive effects. An eye irritant. A very dangerous fire hazard when exposed to heat or flame. Violent reaction with benzene sulfonyl chloride. When heated to decomposition it emits toxic fumes of NOx.


In mice, NMF is metabolized mainly to carbon dioxide, which is exhaled with the breath, and to methylamine, which is excreted with the urine (Kestell et al 1985). Of the radioactivity injected with [14C]formyl-NMF (400 mg/kg), 39% was exhaled as carbon dioxide. The amount of the drug excreted unchanged in the urine in mice was only 26% (Brindley et al 1982) and 15% of the dose was metabolized to methylamine (Kestell et al 1985). A mercapturate, N-acetyl-S-(Nmethylcarbamoyl)cysteine was identified as a major metabolite of NMF in the urine of mice, rats and patients (Kestell et al 1986). Formation of this novel metabolite involves oxidation of the formyl moiety and subsequent conjugation with glutathione (Threadgill et al 1987). On GLC analysis of the urine of mice which had received NMF, small amounts of formamide were also detected (Brindley et al 1982). Some evidence suggests that this metabolite was actually N-Hydroxy-methylformamide, the immediate product of N-methyl C-hydroxyla-tion of NMF, and not formamide (Kestell et al 1985). A^Hydroxymethylformamide, like N-hydroxymethyl-N-methylformamide, the principal metabolite of dimethylformamide, is thermally labile and breaks down to give formamide and formaldehyde; but it is stable in aqueous solution. In alkaline solution N-hydroxymethylformamide undergoes facile hydrolysis (Cooksey et al 1983). Only 14% of the radioactivity injected with [14C]methyl-NMF was exhaled as labeled carbon dioxide (Kestell et al 1985). Formate was not a urinary metabolite of NMF in mice (Kestell et al 1985).
When [14C]methyl-NMF (400 mg/kg) was injected i.p. in mice and drug plasma concentrations were determined during the first 24 h, the plasma concentration of radioactivity versus time curve was superimposable on the curve obtained by measuring unmetabolized NMF by GLC (Brindley et al 1982). Therefore, the metabolites of NMF appear to be rapidly eliminated from the blood into the urine. Radioactivity in the plasma was measurable for 8 days post NMF administration, but NMF was not detectable by GLC beyond 24 h after injection (Brindley et al 1982). The areas under the plasma concentration versus time curves after i.p., i.v. and oral administration of NMF in mice were found to be very similar (Brindley et al 1982). Similarly, the bioavailability of NMF was high in patients in a phase I clinical trial (Brindley et al 1983).
Contrary to an earlier report which claimed that NMF was biotransformed to formaldehyde by a rat liver homogenate (Barnes and Ranta, 1972), recent findings have shown that NMF does not undergo appreciable metabolism in vitro. Neither formaldehyde (or a formaldehyde precursor) could be detected as a metabolite of NMF in liver preparations or hepatocytes, nor was metabolism measurable as observed by the disappearance of substrate (Gescher et al 1982). However, NMF labeled with [14C] either in the methyl or the formyl moiety was metabolized by mouse liver microsomes in the presence of NADPH to a species which was bound covalently to microsomal protein. This covalent binding in vitro was abolished in the presence of glutathione (Pearson et al 1987a). Drug-derived radioactivity was incorporated into or bound to hepatic proteins also when [14C]NMF was administered to mice (Pearson et al 1987a). Intraperitoneal injection of NMF (200 mg/kg) in mice caused depletion of the liver glutathione pools by 79% 2 h after administration (Pearson et al 1987b). Incubation of isolated mouse hepatocytes with 7 mM NMF, which was the peak plasma concentration achieved after administration of 400 mg/kg in mice (Brindley et al 1982), led to a significant decrease in intracellular glutathione levels without an increase in glutathione disulfide (Whitby et al 1984b). Similarly, concentrations of NMF in the 0.1 M range caused glutathione depletion in cultures of human colon carcinoma cells (Cordeiro and Savarese, 1984, Cordeiro and Savarese, 1986). This depletion was accompanied by inhibition of cell growth.


Dry it over molecular sieves for 2days, then distil it under reduced pressure through a column packed with glass helices. Fractionally crystallise it by partial freezing and the solid portion is distilled in a vacuum. [Beilstein 4 IV 170.]

N-メチルホルムアミド 上流と下流の製品情報



N-メチルホルムアミド 生産企業

Global( 221)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Yancheng Green Chemicals Co.,Ltd
86-515-87883652 CHINA 73 58
Hefei TNJ Chemical Industry Co.,Ltd.
86-0551-65418684 18949823763
86-0551-65418684 China 2754 55
Foshan Sanshui Jingze Chemical Co.,Ltd
025-52279193 CHINA 61 58
Hebei Miaobian Biotechnology Co., Ltd
17733850068 +8617733850068 CHINA 288 58
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21869 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22623 55
Anhui Royal Chemical Co., Ltd.
+86-025-86655873 CHINA 537 55
Hebei Chishuo Biotechnology Co., Ltd.
13292891350 +86 311 66567340 CHINA 996 58
career henan chemical co
+86-371-86658258 CHINA 30037 58
+86 18953170293
+86 0531-67809011 CHINA 2995 58


  • 123-39-7
  • EK 7011
  • ek7011
  • Formamide,N-methyl-
  • Formylmethylamine
  • Methylformamide
  • Monomethylformamide
  • N-Methylformamide>99%
  • (Methylamino)formaldehyde
  • N-Methylformamide,N-Formylmethylamine
  • N-MethylforMaMide, 99+% 5GR
  • N-MethylforMaMide, 99+% , 99+%
  • N-Methyl formamide (NMF)
  • n-methyl-formamid
  • n-methyl-formicacidamid
  • N-Methylmethanamide
  • N-Monomethylformamide
  • NSC 3051
  • nsc3051
  • X 188
  • x188
  • N-Methylformamide>
  • N-メチルホルムアミド
  • N-ホルミルメチルアミン
  • N-モノメチルホルムアミド
  • (メチルアミノ)ホルムアルデヒド
  • N-メチルホルムイミド酸
  • Nメチルホルムアミド
  • N-メチルホルムアミド(NMF)
  • N‐メチルホルムアミド
  • N-メチルホルムアミド, 99%
Copyright 2017 © ChemicalBook. All rights reserved